Asia F. A.
- Country
- Spain
- Department
- Oncology
Research Overview
- A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase 3 Randomized Double-Blind Trial of Ociperlimab and Tislelizumab vs. Pembrolizumab in PD-L1-Selected Advanced Non-Small Cell Lung Cancer
- Pharmacokinetic Comparison of ABP 234 and Pembrolizumab in Adjuvant Therapy for Early-stage Non-squamous Non-small Cell Lung Cancer
Data & Insights
Has run more than one trial at 27 of 124 partner sites.
Specializations
Lung Cancer Specialization
This investigator specializes in treating various stages of non-small cell lung cancer (NSCLC), with particular emphasis on both early-stage and advanced disease states.
- Early-stage non-squamous NSCLC
- Advanced and metastatic NSCLC
- Locally advanced unresectable NSCLC
Their expertise extends to managing patients requiring adjuvant treatment following surgical resection and platinum-based chemotherapy.
Immunotherapy Focus
The investigator has developed significant expertise in immunotherapy treatments for lung cancer, particularly focusing on immune checkpoint inhibitors and novel therapeutic combinations.
- PD-L1 targeted therapies
- Anti-TIGIT antibody treatments
- Combination immunotherapy approaches
Their work encompasses both established immunotherapy agents and emerging therapeutic antibodies.
Treatment Innovation
The investigator's work includes evaluation of novel therapeutic approaches and comparative assessment of different treatment modalities in lung cancer.
- Biosimilar evaluation
- Combination therapy assessment
- Treatment sequencing strategies
Their expertise includes assessment of pharmacokinetic profiles and therapeutic equivalence studies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.